Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM

[1]  J. Holst,et al.  Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. , 1996, The Journal of clinical endocrinology and metabolism.

[2]  D. Hargrove,et al.  Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration. , 1995, Metabolism: clinical and experimental.

[3]  J. Holst,et al.  Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects , 1995, Diabetes.

[4]  J. Holst,et al.  Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. , 1995, The Journal of clinical endocrinology and metabolism.

[5]  J. Holst,et al.  Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM , 1994, Diabetes Care.

[6]  J. Holst,et al.  Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans , 1994, Diabetes.

[7]  B. Gallwitz,et al.  Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. , 1993, European journal of biochemistry.

[8]  J. Holst,et al.  Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7–36 Amide and Glucagonlike Peptide-1 7–37 in Healthy Subjects Are Indistinguishable , 1993, Diabetes.

[9]  M. Nauck,et al.  Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. , 1993, The Journal of clinical endocrinology and metabolism.

[10]  M. Nauck,et al.  Gut hormones and diabetes mellitus. , 1992, Diabetes/metabolism reviews.

[11]  J. Holst,et al.  Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. , 1992, The New England journal of medicine.

[12]  D. Nathan,et al.  Insulinotropic Action of Glucagonlike Peptide-I-(7–37) in Diabetic and Nondiabetic Subjects , 1992, Diabetes Care.

[13]  C. Orskov.  Glucagon-like peptide-1, a new hormone of the entero-insular axis. , 1992, Diabetologia.

[14]  J. Habener,et al.  Homologous desensitization of the insulinotropic glucagon-like peptide-I (7-37) receptor on insulinoma (HIT-T15) cells. , 1991, Endocrinology.

[15]  B. Göke,et al.  Priming effect of glucagon-like peptide-1 (7-36) amide, glucose-dependent insulinotropic polypeptide and cholecystokinin-8 at the isolated perfused rat pancreas. , 1991, Biochimica et biophysica acta.

[16]  G. Weir,et al.  Glucagonlike Peptide I (7–37) Actions on Endocrine Pancreas , 1989, Diabetes.

[17]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[18]  J. Holst,et al.  Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). , 1987, Scandinavian journal of clinical and laboratory investigation.

[19]  J. Holst.  Evidence that peak II GLI or enteroglucagon is identical to the C-terminal sequence (residues 33–69) of glicentin , 1983, Regulatory Peptides.

[20]  R. Holman,et al.  THE BASAL PLASMA GLUCOSE: A SIMPLE RELEVANT INDEX OF MATURITY‐ONSET DIABETES , 1981, Clinical endocrinology.

[21]  R. Holman,et al.  DIABETES: THE QUEST FOR BASAL NORMOGLYCÆMIA , 1977, The Lancet.

[22]  J. D. George.  New clinical method for measuring the rate of gastric emptying: the double sampling test meal. , 1968, Gut.